Infusion of one MPC expanded cord unit and one unexpanded cord unit + Infusion of two unexpanded cord blood units.
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 34/100
34
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Myelogenous Leukemia
Conditions
Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma, Hodgkin's Disease
Trial Timeline
Aug 1, 2013 → May 5, 2017
NCT ID
NCT01854567About Infusion of one MPC expanded cord unit and one unexpanded cord unit + Infusion of two unexpanded cord blood units.
Infusion of one MPC expanded cord unit and one unexpanded cord unit + Infusion of two unexpanded cord blood units. is a phase 3 stage product being developed by Mesoblast for Acute Myelogenous Leukemia. The current trial status is completed. This product is registered under clinical trial identifier NCT01854567. Target conditions include Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma.
What happened to similar drugs?
20 of 20 similar drugs in Acute Myelogenous Leukemia were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
17
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01854567 | Phase 3 | Completed |
Competing Products
20 competing products in Acute Myelogenous Leukemia